Fosfomycin Resistance in *Escherichia coli*, Pennsylvania, USA

Hind Alrowais, Christi L. McElheny, Caressa N. Spychala, Sangeeta Sastry, Qinglan Guo, Adeel A. Butt, Yohei Doi

Fosfomycin resistance in *Escherichia coli* is rare in the United States. An extended-spectrum β-lactamase–producing *E. coli* clinical strain identified in Pennsylvania, USA, showed high-level fosfomycin resistance caused by the *fosA3* gene. The IncFII plasmid carrying this gene had a structure similar to those found in China, where fosfomycin resistance is commonly described.

Fosfomycin is a phosphonic acid derivative with antibacterial activity against a wide range of gram-negative pathogens and some gram-positive pathogens. It inhibits bacterial cell wall synthesis and is bactericidal against most *Escherichia coli* strains, as well as many strains of other members of the family *Enterobacteriaceae*. In the United States, only an oral formulation containing fosfomycin tromethamine is approved for clinical use.

Because of increasing resistance of *E. coli* strains to other commonly used agents, such as ciprofloxacin and trimethoprim/sulfamethoxazole, fosfomycin has become one of the first-line agents recommended for treatment of uncomplicated urinary tract infection. A recent study of *E. coli* strains collected at veterans’ hospitals in the United States included ciprofloxacin-resistant and extended-spectrum β-lactamase–producing strains. These strains had 98%–99% susceptibility to fosfomycin (1). However, susceptibility data on fosfomycin are relatively limited overall because this agent is not routinely tested in most clinical microbiology laboratories.

Several fosfomycin resistance mechanisms have been described in *E. coli*, including reduced permeability, modification of the *murA* gene target, and modification of fosfomycin (2). In *E. coli*, the plasmid-mediated fosfomycin resistance gene *fosA3*, which encodes a glutathione S-transferase, was first identified in a fosfomycin-resistant *E. coli* strain in Japan (3). This enzyme modifies fosfomycin, thus inactivating the agent and conferring high-level fosfomycin resistance. The *foxA3* gene has been reported from only countries in eastern Asia, especially China. We report a case of persistent colonization with a *foxA3*-carrying *E. coli* strain in a patient in Pennsylvania, USA.

The Study

The patient was a woman with multiple hospitalizations related to sickle cell crises and end-stage kidney disease; she was receiving peritoneal dialysis. She produced minimal amounts of urine and had frequent urinary tract infections due to extended-spectrum β-lactamase–producing *E. coli*. She did not have history of travel to eastern Asia, from which all reports of *foxA3* have so far originated. The first available *E. coli* strain from this patient, ECRB1, was isolated from a urine sample in 2007 and was reported as a multidrug-resistant strain harboring *bla*<sub>CTX-M-65</sub> and *rmtB* (4).

She came to a hospital in 2010 because of a power outage in her home. During this brief hospitalization, a culture collected from the peritoneal catheter exit site grew *E. coli* strain YD472. This strain was found to be highly resistant to fosfomycin, which initiated the present investigation. She had received multiple antimicrobial agents, including cefazolin, ceftriaxone, ciprofloxacin, moxiﬂoxacin, azithromycin, and trimethoprim/sulfamethoxazole, in the prior 5 years, but she had not received fosfomycin according to available medical records.

*E. coli* YD472 was highly resistant to fosfomycin (MIC > 1,024 µg/mL by Etest), which was confirmed by using the agar dilution method with Mueller-Hinton agar and glucose-6-phosphate (25 µg/mL) as an additive, as endorsed by the Clinical and Laboratory Standards Institute (5). Given this high-level resistance, PCR was conducted on YD472 to identify *foxA3* and *fosC2*, which have been reported as acquired fosfomycin resistance genes among recent *E. coli* strains in Japan, China, and South Korea (3,6,7). A PCR result was positive for *foxA3*, which was confirmed by sequencing. The *foxA3* gene was transferable to *E. coli* TOP10 by electroporation of the total plasmid extracted from YD472. The *E. coli* TOP10 transformant strain harboring the *foxA3*-encoding plasmid pYHCC was resistant to cefotaxime, gentamicin, and fosfomycin.

We then sequenced the entire plasmid in pYHCC by using single-molecule real-time sequencing (Pacific Biosciences, Menlo Park, CA, USA) as described (8). Sequencing in a single cell resulted in a full-length plasmid that could then be circularized and finished (mean coverage 1,325×). The sequence was manually annotated by using...

pYHCC is an 80,206-bp circular plasmid with a G+C content of 51.8% and a typical IncFII replicon, which is classified as F2:A–:B– by replicon sequence typing (9). It encodes 121 genes (including hypothetical genes) and harbors a 13-kb multidrug resistance region and a 67-kb R100-like backbone region. The backbone region contains genes for replication, transfer, and maintenance. This backbone of pYHCC contains 24 tra genes and 7 trb genes. The structure of pYHCC is most closely related to that of pXZ, a 77-kb IncFII, fosA3-carrying plasmid reported from E. coli strains isolated from diseased chickens and ducks in China (99% identity with 95% coverage) (Figure 1) (10). It also shares high similarities (99% identity with 84%–87% coverage) with other fosA3-carrying E. coli plasmids reported, including pHN7A8 from a dog in China (11), pHN3A11 from a cat in China, pHK23a from a pig in Hong Kong (12), and pFOS-HK151325 from a human in Hong Kong (13).

A feature that distinguishes pYHCC from pXZ and contributes to the size difference of the plasmids is insertion of ISCroI between trbJ and trbF in pYHCC. Plasmid pYHCC carries 4 antimicrobial resistance genes, all of which are in the multidrug resistance region. These genes are blaCTX-M-65 (confering cephalosporin resistance), fosA3 (conferring fosfomycin resistance), blaTEM-1 (confering ampicillin resistance), and rmtB (conferring aminoglycoside resistance). The fosA3 gene and its downstream open reading frame encoding a putative 172-aa protein is flanked by 2 tandem copies of IS26. This arrangement is identical to that in pXZ and pHN7A8, except that pXZ carries blaCTX-M-24 instead of blaCTX-M-65. The blaCTX-M-24 and blaCTX-M-65 gene products differ by only 1 aa (Val for CTX-M-65 and Ala for CTX-M-24 at position 77).

A total of 6 E. coli isolates were collected from the patient during 2007–2010, including the isolates reported...
here and previously (4). All isolates were obtained from urine samples, except for YD472, which was cultured from the peritoneal catheter exit site. Pulsed-field gel electrophoresis (PFGE) with XbaI as the restriction enzyme showed that all isolates had identical banding patterns. Furthermore, 5 of the 6 isolates, including the first isolate from 2007, were resistant to fosfomycin and positive for fosA3, rmtB, and blaCTX-M-9-group by PCR. E. coli TOP10 transformants harboring fosA3-carrying plasmids were generated from each of these 5 isolates.

The plasmids were then extracted and digested with restriction enzyme EcoRI. The resulting restriction profile was nearly identical across the plasmids except for pYHCC from YD472, which had a shift of a band from ≈8 kb to ≈11 kb (Figure 2). This shift approximated the size difference between pYHCC and pXZ, and further suggested pXZ as the origin of pYHCC.

Conclusions

The first reported clinical E. coli isolate carrying fosA3 was identified in Japan in 2006 (3), but fosA3-carrying E. coli isolates have also been identified in pigs in China as far back as in 2004 (14). Although the patient in Pennsylvania lacked a relevant travel history, the timeline and structural similarities of these fosA3-carrying plasmids make it plausible that this multidrug resistance plasmid originated in E. coli in Asia and moved to the continental United States by human travel or importation of food products. Emergence of E. coli with high-level fosfomycin resistance is a clinically relevant event, especially in the United States, where fosfomycin is increasingly used for empiric treatment of urinary tract infection in the absence of routine drug susceptibility testing.

This study was supported by the Saudi Arabian Cultural Mission. Y.D. was also supported by research grants from the National Institutes of Health (R01AI104895 and R21AI107302).

Y.D. has served on an advisor board for Shionogi Inc., consulted for Melinta Therapeutics, and received research funding from Merck & Co. for a study unrelated to this study.

Dr. Alrowais is a research trainee at the University of Pittsburgh, Pittsburgh, Pennsylvania. Her research interests include emerging mechanisms of antimicrobial resistance in E. coli.

References


Address for correspondence: Yohei Doi, Division of Infectious Diseases, University of Pittsburgh School of Medicine, S829 Sciffl Hall, 3550 Terrace St, Pittsburgh, PA 15261 USA; email: yod4@pitt.edu

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 11, November 2015

2047